Acutus Medical raises $170M to push it further into arrhythmia treatment

EKG rhythm
The former Fierce 15 winner’s recent acquisition of Rhythm Xience, manufacturer of a family of FDA-cleared catheter introducer devices, moves the company toward its goal of addressing the entire patient care continuum. (Pixabay)

On the heels of acquiring a catheter hardware developer and announcing a slew of new partnerships, Acutus Medical has now secured $170 million to move further into heart arrhythmia treatment delivery and monitoring.

The financing includes a $100 million series D raise and $70 million in credit provided by Deerfield Management and OrbiMed’s Credit and Royalties Fund. The proceeds are expected to boost the company’s global business development and commercialization of its vascular access products.

The venture capital round, meanwhile, included new investors 8VC, Opaleye Management, Pura Vida Investments and others, alongside Acutus’ returning backers Advent Venture Partners, Xeraya Capital and GE Ventures, plus OrbiMed and Deerfield.

The MedTech Conference

The MedTech Conference: September 23-25, Boston, MA

With over 3,000 attendees from 35 countries, The MedTech Conference features world-class plenary speakers, cross-cutting educational programming and business development opportunities. This is a prime opportunity to network, conduct business and share insights with medtech leaders. Register before July 26th and save $200!

"Advanced imaging, individualized therapy and increased procedural efficiency are needed components to progress the electrophysiology field,” Acutus CEO Vince Burgess said in a statement—referring to the former Fierce 15 winner’s recent acquisition of Rhythm Xience, manufacturer of a family of FDA-cleared catheter introducer devices, as the company sets a goal of addressing the entire patient care continuum.

RELATED: With cardiac imaging set, Acutus looks to move deeper into arrhythmia treatments, monitoring

Previously, Acutus received an FDA clearance for its AcQMap cardiac mapping system for monitoring an atrial fibrillation ablation treatment in real time.

The company also announced partnerships with Peerbridge, maker of a seven-day wearable electrocardiogram (ECG), as well as with Cardiac Designs, which will focus on long-term remote patient monitoring with Acutus’ QCheck handheld ECG and mobile app.

Additionally, its team up with MedFact will allow Acutus to distribute its robotically enabled radiofrequency ablation catheter alongside its magnetic and ultrasound-based navigation and mapping systems.

“Cardiac ablation is a rapidly growing market and treatment efficiency needs to improve,” said Drew Oetting, founding partner at 8VC. “Many people, including dear friends of ours, have faced these procedures and Acutus' innovative and effective tools look to add even more safety.”

Suggested Articles

Prenatal blood test developer Cradle Genomics has secured $17.1 million to help build out its laboratory operations.

A TGen-led research team found that increased activity of the gene AEBP1 drives severe liver fibrosis in nonalcoholic steatohepatitis.

Days after announcing its R&D chief was stepping down, Gilead announced it will be buying a few of Novartis’ unwanted early-stage infection assets.